Abern MR - Search Results

1

Predictors of fluoroquinolone-resistant bacteria in the rectal vault of men undergoing prostate biopsy.

Tan WP, Papagiannopoulos D, Latchamsetty KC, Wilson N, O'Block N, Raff L, Mena Lora A, Coogan CL, Abern MR. Tan WP, et al. Among authors: abern mr. Prostate Cancer Prostatic Dis. 2019 May;22(2):268-275. doi: 10.1038/s41391-018-0092-3. Epub 2018 Oct 2. Prostate Cancer Prostatic Dis. 2019. PMID: 30279581

2

Marital status independently predicts testis cancer survival--an analysis of the SEER database.

Abern MR, Dude AM, Coogan CL. Abern MR, et al. Urol Oncol. 2012 Jul-Aug;30(4):487-93. doi: 10.1016/j.urolonc.2010.03.005. Epub 2010 Sep 26. Urol Oncol. 2012. PMID: 20870430

3

An update on TroVax for the treatment of progressive castration-resistant prostate cancer.

Abern M, Kaufman HL, Latchamsetty K. Abern M, et al. Onco Targets Ther. 2011;4:33-41. doi: 10.2147/OTT.S14271. Epub 2011 May 24. Onco Targets Ther. 2011. PMID: 21691576 Free PMC article.

4

The characteristics of bladder cancer after radiotherapy for prostate cancer.

Abern MR, Dude AM, Tsivian M, Coogan CL. Abern MR, et al. Urol Oncol. 2013 Nov;31(8):1628-34. doi: 10.1016/j.urolonc.2012.04.006. Epub 2012 May 9. Urol Oncol. 2013. PMID: 22575239

5

Characteristics and outcomes of tumors arising from the distal nephron.

Abern MR, Tsivian M, Polascik TJ, Coogan CL. Abern MR, et al. Urology. 2012 Jul;80(1):140-6. doi: 10.1016/j.urology.2012.03.034. Epub 2012 May 23. Urology. 2012. PMID: 22626576

6

African-American men with low-grade prostate cancer have higher tumor burdens: results from the Duke Prostate Center.

Tsivian M, Bañez LL, Keto CJ, Abern MR, Qi P, Gerber L, Moul JW, Polascik TJ. Tsivian M, et al. Among authors: abern mr. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):91-4. doi: 10.1038/pcan.2012.39. Epub 2012 Oct 2. Prostate Cancer Prostatic Dis. 2013. PMID: 23032361

7

Race is associated with discontinuation of active surveillance of low-risk prostate cancer: results from the Duke Prostate Center.

Abern MR, Bassett MR, Tsivian M, Bañez LL, Polascik TJ, Ferrandino MN, Robertson CN, Freedland SJ, Moul JW. Abern MR, et al. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):85-90. doi: 10.1038/pcan.2012.38. Epub 2012 Oct 16. Prostate Cancer Prostatic Dis. 2013. PMID: 23069729

8

Characteristics of patients diagnosed with both melanoma and renal cell cancer.

Abern MR, Tsivian M, Coogan CL, Kaufman HL, Polascik TJ. Abern MR, et al. Cancer Causes Control. 2013 Nov;24(11):1925-33. doi: 10.1007/s10552-013-0267-0. Epub 2013 Jul 30. Cancer Causes Control. 2013. PMID: 23897487

9

Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.

Allott EH, Abern MR, Gerber L, Keto CJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Moorman PG, Freedland SJ. Allott EH, et al. Among authors: abern mr. Prostate Cancer Prostatic Dis. 2013 Dec;16(4):391-7. doi: 10.1038/pcan.2013.48. Epub 2013 Oct 8. Prostate Cancer Prostatic Dis. 2013. PMID: 24100644 Free PMC article.

10

The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer.

Abern MR, Terris MK, Aronson WJ, Kane CJ, Amling CL, Cooperberg MR, Freedland SJ. Abern MR, et al. Cancer. 2014 Jun 1;120(11):1656-62. doi: 10.1002/cncr.28647. Epub 2014 Mar 19. Cancer. 2014. PMID: 24647966 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

96 results

Search Page